Cerus
Concord
About Cerus
Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $235.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2020)
- Ticker: nasdaq:CERS
- Website: cerus.com
- Phone: 9252886001
Industries & Categories
Biotechnology, Health Care, Industrial Automation, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cerus-33552 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.